Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Conditions:   Lung Cancer Adenocarcinoma;   Lung Cancer Squamous Cell;   Mesothelioma; Lung Intervention:   Sponsor:   Sohag University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions:   Solid Tumors, Adult;   Solid Tumor;   Mesothelioma (MPM);   Epithelioid Hemangioendothelioma (EHE);   NF2 Deficient Mesothelioma;   Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes;   NF2 Deficiency;   YAP1 or TAZ Gene Fusions Intervention:   Drug: IK-930 Sponsor:   Ikena Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Conditions:   Lung Cancer Adenocarcinoma;   Lung Cancer Squamous Cell;   Mesothelioma; Lung Intervention:   Sponsor:   Sohag University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions:   Solid Tumors, Adult;   Solid Tumor;   Mesothelioma (MPM);   Epithelioid Hemangioendothelioma (EHE);   NF2 Deficient Mesothelioma;   Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes;   NF2 Deficiency;   YAP1 or TAZ Gene Fusions Intervention:   Drug: IK-930 Sponsor:   Ikena Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Conditions:   Lung Cancer Adenocarcinoma;   Lung Cancer Squamous Cell;   Mesothelioma; Lung Intervention:   Sponsor:   Sohag University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions:   Solid Tumors, Adult;   Solid Tumor;   Mesothelioma (MPM);   Epithelioid Hemangioendothelioma (EHE);   NF2 Deficient Mesothelioma;   Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes;   NF2 Deficiency;   YAP1 or TAZ Gene Fusions Intervention:   Drug: IK-930 Sponsor:   Ikena Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Conditions:   Lung Cancer Adenocarcinoma;   Lung Cancer Squamous Cell;   Mesothelioma; Lung Intervention:   Sponsor:   Sohag University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions:   Solid Tumors, Adult;   Solid Tumor;   Mesothelioma (MPM);   Epithelioid Hemangioendothelioma (EHE);   NF2 Deficient Mesothelioma;   Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes;   NF2 Deficiency;   YAP1 or TAZ Gene Fusions Intervention:   Drug: IK-930 Sponsor:   Ikena Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2022 Category: Research Source Type: clinical trials

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions:   Pancreatic Cancer;   Breast Cancer;   Gastric Cancer;   Non-small Cell Lung Cancer;   Cervical Cancer;   Endocervical Cancer;   Squamous Cell Carcinoma of Head and Neck;   Bladder Urothelial Cancer;   Colorectal Carcinoma;   Esophageal Cancer;   Ovarian Cancer;   Re nal Cell Carcinoma;   Prostate Cancer;   Melanoma;   Mesothelioma;   Cholangiocarcinoma Interventions:   Drug: NGM831;   Drug: NGM831 plus pembrolizumab Sponsor:   NGM Biopharmaceuticals, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2022 Category: Research Source Type: clinical trials